Sign in

NCT03966443Recruiting

Fluciclovine PET/CT in Multiple Myeloma Patients

PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose

Source: ClinicalTrials.gov · Last updated 30 May 2019 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients

Status (registry)
Recruiting
Study type
Observational
Enrollment
10 (estimated)
First submitted
27 May 2019
Start date
1 Mar 2019
Primary completion date
31 Jan 2020
Lead sponsor
Oslo University Hospital
NCT number
NCT03966443

What you commit to

  • Study type: Observational
  • Planned participants: 10
  • From 1 Mar 2019 to the primary completion date, 31 Jan 2020
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients with contraindications to ASCT treatment

Who the study is looking for

  • Multiple myeloma patients suitable for ASCT treatment

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Oslo University Hosptal
Coordinator of this site? Confirm its status
OsloNorwayRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.